Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
Noosa News24 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
General23 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
Noosa News21 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
General23 hours agoTruck driver charged with causing death by dangerous driving after highway crash